Alnylam Pharmaceuticals, Inc.
XETRA: DUL.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,100
- Headquarters
- Cambridge, United States
- IPO year
- 2007
- Market cap
- €33.6B
- Website
- https://www.alnylam.com
Loading DUL…
Loading profile data…Frequently asked questions about DUL
What does Alnylam Pharmaceuticals, Inc. (DUL.DE) do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
Where does DUL.DE trade?
Alnylam Pharmaceuticals, Inc. (DUL.DE) trades on the Deutsche Börse.
What sector is DUL.DE in?
Alnylam Pharmaceuticals, Inc. (DUL.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alnylam Pharmaceuticals, Inc.?
Yvonne L. Greenstreet is the chief executive officer of Alnylam Pharmaceuticals, Inc. (DUL.DE).
Where is Alnylam Pharmaceuticals, Inc. headquartered?
Alnylam Pharmaceuticals, Inc. is headquartered in United States.
Does DUL.DE pay a dividend?
Alnylam Pharmaceuticals, Inc. (DUL.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DUL.DE go public?
Alnylam Pharmaceuticals, Inc. (DUL.DE) completed its initial public offering in 2007.